A Phase 3 interventional study of Ibuprofen 250 mg / Acetaminophen 500 mg and Ibuprofen 250 mg in Fever, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-07.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing ibuprofen in Fever — none open to participants now, none under way, none of them phase 3. Ibuprofen · Fever.
Among the 19 studies testing ibuprofen in Fever, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2016, is one of 6 in phase 3, and was the 15th registered.
438 studies on the registry are indexed under Fever; 55 are open to participants now.
Browse Fever studies →None of the 19 studies testing ibuprofen in Fever is open now. The open studies under Fever, anywhere →
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 38 Fever studies recruiting now, 18 (47%) set no upper age limit and 14 (37%) stop at 75 or younger; 22 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 290 is above the median of 123 across 271 interventional studies indexed under Fever.
Median enrollment 119 across the 18 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 5 studies filed under Fever — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing ibuprofen in Fever, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single dose study that will evaluate the efficacy and safety of a Fixed Dose Combination Ibuprofen 250 mg/ Acetaminophen 500 mg tablet in healthy male patients with fever. Results for the Fixed Dose Combination product will be compared to the individual components Ibuprofen 250 mg and Acetaminophen 500 mg and also compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of 2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg by mouth
Drug: Ibuprofen 250 mg / Acetaminophen 500 mg
Single dose of 2 caplets of IBU 125 mg by mouth
Drug: Ibuprofen 250 mg
Single dose of 1 APAP 500 mg caplet + 1 placebo caplet by mouth
Drug: Acetaminophen 500 mg
Single dose of 2 caplets of Placebo by mouth
Drug: Placebo
Drug page: Ibuprofen
Ibuprofen 250 mg / Acetaminophen 500 mg
Also known as: IBU 250 / APAP 500
Ibuprofen 250 mg
Also known as: IBU 250
1 APAP 500 mg caplet
Also known as: APAP 500
Placebo tablet
Time Weighted Sum of Temperature Difference (WSTD) From 0 to 8 Hours
WSTD 0-8 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 and 8 hours). Temperature difference was defined as baseline temperature (at 0 hour) minus the post-baseline temperature at each time point up to 8 hours (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 and 8 hours).
Time frame: 0 to 8 hours post-dose
Time Weighted Sum of Temperature Differences (WSTD) From Baseline Through Hours 2, 4 and 6
WSTD 0-2, 0-4 and 0-6 was defined as time-weighted sum of temperature differences over each specified time interval (0-2 hour, 0-4 hour and 0-6 hour), weighted by time elapsed between each 2 consecutive time points post treatment (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6 hour), within each time interval. Temperature difference was defined as baseline temperature (at 0 hour) minus the post-baseline temperature at each time point within each specified time interval: 1) 0-2 hour (20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes) , 2) 0-4 hour (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4 hour), 3) 0-6 hour (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6 hour).
Time frame: 0 to 2 hours postdose, 0 to 4 hours postdose, 0 to 6 hours postdose
Time to Return to Normal Body Temperature
Time to return to normal body temperature was defined as time from initial measurement of normal body temperature (at baseline; before administration of first test dose of RSE to induce pyrexia) till the time at which normal temperature was achieved again after pyrexia. Normal body temperature was defined as the last non-missing body temperature value, assessed prior to or at the time of first RSE test dose.
Time frame: Baseline (pre-dose) up to 8 hours post dose
Time to Rescue Medication
Time to rescue medication (other than study treatment) (in minutes) was defined as time from first dosing of study medication to the time a participant first takes a rescue medication, or to the end of the study time for participants that do not take any rescue medication prior to the end of the study. The rescue medication was defined as medication received for the treatment of fever during the time period from the administration of study medication to the time of end of the study.
Time frame: 0 to 8 hours post dose
Time Weighted Sum of Temperature Difference From 6 to 8 Hours
WSTD 6-8 was defined as time-weighted sum of temperature differences between 6 to 8 hours post-dose, weighted by time elapsed between each 2 consecutive time points within 6 to 8 hours (6.5, 7, 7.5 and 8 hours). Temperature difference was defined as temperature at 6 hours minus the temperature at specified time points (6.5, 7, 7.5 and 8 hours).
Time frame: 6 to 8 hours postdose
Number of Participants With Treatment Emergent Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug and up to 24 hours after discharge (up to 32 hours) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.
Time frame: Baseline up to 24 hours after discharge (up to 32 hours)
| Milestone | Placebo | Ibuprofen 250 mg+Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 500 mg |
|---|---|---|---|---|
| Started | 29 | 87 | 87 | 87 |
| Completed | 25 | 80 | 81 | 81 |
| Not completed | 4 | 7 | 6 | 6 |
| Withdrew: Adverse event | 4 | 6 | 5 | 6 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 0 |
WSTD 0-8 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 and 8 hours). Temperature difference was defined as baseline temperature (at 0 hour) minus the post-baseline temperature at each time point up to 8 hours (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 and 8 hours).
| degrees fahrenheit | Placebo | Ibuprofen 250 mg+Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 500 mg |
|---|---|---|---|---|
| Time Weighted Sum of Temperature Difference (WSTD) From 0 to 8 Hours | 9.28 ± 6.395 | 12.54 ± 5.519 | 11.09 ± 6.355 | 12.39 ± 6.278 |
WSTD 0-2, 0-4 and 0-6 was defined as time-weighted sum of temperature differences over each specified time interval (0-2 hour, 0-4 hour and 0-6 hour), weighted by time elapsed between each 2 consecutive time points post treatment (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6 hour), within each time interval. Temperature difference was defined as baseline temperature (at 0 hour) minus the post-baseline temperature at each time point within each specified time interval: 1) 0-2 hour (20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes) , 2) 0-4 hour (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4 hour), 3) 0-6 hour (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6 hour).
| degrees fahrenheit | Placebo | Ibuprofen 250 mg+Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 500 mg |
|---|---|---|---|---|
| WSTD 0-2 | -0.42 ± 1.827 | 0.48 ± 1.829 | -0.19 ± 1.856 | 0.21 ± 1.732 |
| WSTD 0-4 | 1.79 ± 3.443 | 3.69 ± 3.152 | 2.61 ± 3.345 | 3.41 ± 3.173 |
| WSTD 0-6 | 5.26 ± 4.833 | 7.95 ± 4.245 | 6.65 ± 4.788 | 7.65 ± 4.604 |
Time to return to normal body temperature was defined as time from initial measurement of normal body temperature (at baseline; before administration of first test dose of RSE to induce pyrexia) till the time at which normal temperature was achieved again after pyrexia. Normal body temperature was defined as the last non-missing body temperature value, assessed prior to or at the time of first RSE test dose.
| minutes | Placebo | Ibuprofen 250 mg+Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 500 mg |
|---|---|---|---|---|
| Time to Return to Normal Body Temperature | 360 (300 to 390) | 330 (240 to 360) | 390 (300 to 420) | 330 (270 to 360) |
Time to rescue medication (other than study treatment) (in minutes) was defined as time from first dosing of study medication to the time a participant first takes a rescue medication, or to the end of the study time for participants that do not take any rescue medication prior to the end of the study. The rescue medication was defined as medication received for the treatment of fever during the time period from the administration of study medication to the time of end of the study.
| minutes | Placebo | Ibuprofen 250 mg+Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 500 mg |
|---|---|---|---|---|
| Time to Rescue Medication | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
WSTD 6-8 was defined as time-weighted sum of temperature differences between 6 to 8 hours post-dose, weighted by time elapsed between each 2 consecutive time points within 6 to 8 hours (6.5, 7, 7.5 and 8 hours). Temperature difference was defined as temperature at 6 hours minus the temperature at specified time points (6.5, 7, 7.5 and 8 hours).
| degrees fahrenheit | Placebo | Ibuprofen 250 mg+Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 500 mg |
|---|---|---|---|---|
| Time Weighted Sum of Temperature Difference From 6 to 8 Hours | 4.96 ± 2.228 | 5.69 ± 1.904 | 5.49 ± 2.261 | 5.84 ± 2.328 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug and up to 24 hours after discharge (up to 32 hours) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.
| Participants | Placebo | Ibuprofen 250 mg+Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 500 mg |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (AEs) | 1 | 1 | 0 | 0 |
Collected over Baseline up to 24 hours after discharge (up to 32 hours). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/29 (0%) | 0/29 (0%) | 1/29 (3.4%) |
| Ibuprofen 250 mg+Acetaminophen 500 mg | 0/87 (0%) | 0/87 (0%) | 1/87 (1.1%) |
| Ibuprofen 250 mg | 0/87 (0%) | 0/87 (0%) | 0/87 (0%) |
| Acetaminophen 500 mg | 0/87 (0%) | 0/87 (0%) | 0/87 (0%) |
| Event | Placebo | Ibuprofen 250 mg+Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 500 mg |
|---|---|---|---|---|
| Ear painEar and labyrinth disorders | 1/29 | 0/87 | 0/87 | 0/87 |
| Rash macularSkin and subcutaneous tissue disorders | 0/29 | 1/87 | 0/87 | 0/87 |
Safety analysis set included all participants who received study medication.
| Age, Continuous(years) | Placebo | Ibuprofen 250 mg+Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 500 mg | Total |
|---|---|---|---|---|---|
| Mean | 28.8 ± 7.97 | 33.4 ± 10.54 | 32.3 ± 10.19 | 32.6 ± 9.99 | 32.4 ± 10.07 |
| Sex: Female, Male(Participants) | Placebo | Ibuprofen 250 mg+Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 500 mg | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 29 | 87 | 87 | 87 | 290 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Ibuprofen 250 mg+Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 500 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 4 | 3 | 13 |
| Not Hispanic or Latino | 27 | 83 | 83 | 84 | 277 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Ibuprofen 250 mg+Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 500 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 1 | 0 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 10 | 20 | 12 | 47 |
| White | 21 | 72 | 65 | 69 | 227 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 4 | 2 | 3 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
Ran from Dec 2016 to primary completion in Dec 2017, 12 months.
Results were first posted in Dec 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen